Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Esperion (ESPR – Research Report). The associated price target remains the same with $16.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including Esperion’s strategic expansion efforts and potential for significant growth. The company has recently secured a licensing and distribution agreement with CSL Seqirus, granting them rights to commercialize NEXLETOL and NEXLIZET in Australia and New Zealand, which is expected to enhance their global footprint. Additionally, a similar agreement with Neopharm Israel further supports Esperion’s strategy to broaden market access and drive long-term growth.
Esperion’s valuation is supported by a clinical net present value model, which anticipates an important revenue inflection point in the latter half of 2024. This is expected to follow label expansions based on positive data from the CLEAR Outcome study. The analyst highlights the potential for higher market penetration, increased chances of success due to clinical progress, and the addition of new commercial geographies as key drivers for the stock’s upside potential. However, risks such as failed clinical trials or funding challenges could impact the achievement of the price target.
Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Viking Therapeutics, and Esperion. According to TipRanks, Pantginis has an average return of -8.1% and a 27.51% success rate on recommended stocks.